CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 513 enrolled
Drug / intervention
V920 Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02314923
NCT02314923Phase 1Completed
CompareCT.gov

A Phase 1 Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects

Merck Sharp & Dohme LLC·interventional·Posted Dec 11, 2014·Updated Feb 5, 2020

In Brief

A Phase 1 clinical trial evaluating V920 Vaccine and Placebo for Ebola Virus. Completed, enrolled 513 participants.

Detailed Summary

Ebola virus has infected and killed people, mostly in Africa. In 2014, the Ebola virus has affected several thousand people. There is no approved effective way to treat or prevent Ebola. Researchers are trying to develop a vaccine for it. This is a study of the anti-Ebola vaccine BPSC-1001 to see if it is safe and to see how it affects people's immune system.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEbola Virus
Countries--
CollaboratorsBioProtection Systems Corporation, Department of Health and Human Services

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 11, 2014
Enrollment StartDec 5, 2014
Primary CompletionJun 23, 2016
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.6 years ago

Interventions

V920 Vaccinebiological

Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.

Placeboother

0.9% Saline